氨柔比星用于小细胞肺癌二线治疗的荟萃分析

Amrubicin as second-line treatment for small-cell lung cancer:a Meta-analysis

目的系统评价氨柔比星治疗小细胞肺癌(small-cell lung cancer,SCLC)的疗效及安全性。方法检PubMed、EMBASE、CNKI及The Cochrane Library等数据库,收集有关氨柔比星治疗SCLC的研究;主要结局指标包括总效率(overall response rate,ORR)、无进展生存率(progression free survival,PFS)、总生存率(overall survival,OS)及不良件。结果共有6项研究纳入,荟萃分析(Meta分析)显示,氨柔比星应用于SCLC二线治疗时的总有效率显著高于对照[RR 1.72,95%CI(1.39,2.14),P=0.000],但总生存率[HR 0.93,95%CI(0.81,1.07),P=0.405]和无进展生存率[H0.98,95%CI(0.83,1.17),P=0.456]与对照组相比无明显差异。结论氨柔比星治疗SCLC的总有效率高于对照组PFS和OS与对照组相比无显著性差异(P=0.405,P=0.456),因此,氨柔比星可作为SCLC的二线治疗药物。

Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer （SCLC）. Methods PubMed, Embase, the Cochrane Library and CNK1 were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival （OS）, progression-free survival （PFS）, overall response rate （ORR） and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group [RR 1.72,95% CI （1.39, 2.14） ,P=0. 000] , the OS, PFS and toxicity were nodnferior to the control group（P=0. 405,P=0. 456）. Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.